Infectious diseases in Vietnam have been increasing, posing tremendous pressure on the healthcare system and creating an urgent demand for a stable, high-quality, and accessible supply of medicines.
Rising Challenges of Infectious Diseases in the New Context
According to the Ministry of Health, infectious diseases will remain a major concern for Vietnam’s healthcare sector in 2025. This trend stems from the country’s tropical monsoon climate, high population density, and aggravating factors such as climate change and environmental pollution - all of which heavily affect the host–pathogen–vector cycle.
Diseases transmitted via the respiratory and digestive tracts, as well as mosquito-borne illnesses, are expected to rise, especially during the summer travel peak in 2025 as mobility increases. In recent months, hospitals in Ho Chi Minh City have reported a surge in dengue cases — such as Ms. Huong from Binh Thanh District, who was hospitalized due to prolonged fever, and Nhi, a 10-year-old from Dong Thap, who had to miss school for nearly two weeks to treat influenza A.
From common seasonal illnesses such as influenza, dengue fever, and hand – foot – mouth disease to emerging infections, their rapid transmission and high incidence rates continue to challenge Vietnam’s healthcare system. Many dengue patients face secondary infections, while in northern provinces, pneumonia cases among children and the elderly are on the rise, leading to hospital overcrowding.
Data from the Ministry of Health show that infectious diseases such as dengue, measles, influenza A (H5N1), and monkeypox remain complex in 2025. In 2024 alone, Vietnam recorded over 141,000 dengue cases (including 28 fatalities), 76,000 cases of hand–foot–mouth disease, 287,548 cases of seasonal influenza, and 38,364 cases of measles-like fever.
Collective Efforts: The Nation Responds, Businesses Join Hands
Aligned with the Ministry of Health’s 2025 goal to effectively control infectious diseases, minimize morbidity and mortality rates, and strengthen readiness for future epidemics and health emergencies, domestic pharmaceutical companies play a vital role in providing healthcare solutions to the community.
In reality, infections such as pneumonia or post-dengue complications still pose high risks to patients. In such cases, medical advances - particularly next-generation antibiotics - have helped doctors improve treatment efficacy, reduce severe complications, and shorten hospital stays.
.jpg)
Ms. Lê Nữ Minh Hoài, Deputy CEO of Imexpharm, delivers the opening remarks at the Imexforum event
in Ho Chi Minh City on July 5, 2025. Photo: Imexpharm.
Imexpharm’s Role in Strengthening National Healthcare Resilience
Vietnamese pharmaceutical companies have proactively invested in production capacity and product diversification. Among them, Imexpharm stands out with its strategic focus on R&D and internationally certified manufacturing systems.
Currently, Imexpharm operates 12 EU-GMP-certified production lines across three EU-GMP manufacturing complexes, forming a strong foundation for producing high-quality medicines that meet hospital demands from central to local levels.
Imexpharm’s antibiotic portfolio spans multiple key therapeutic groups - particularly those recommended in clinical treatment guidelines - including: Amoxicillin + Clavulanic Acid: Available in both oral and injectable formulations; Avibactam: Critical in treating multidrug-resistant bacterial strains; Colistin: A last-resort therapy for difficult-to-treat Gram-negative infections; Quinolones: Essential for respiratory and urinary tract infections.
Notably, Imexpharm applies enzymatic technology in antibiotic production, replacing most traditional solvents and chemicals to ensure product purity and safety. The company also tailors antibiotic applications to different infection severities - from mild community-acquired respiratory infections to severe cases in hospitals and ICUs - while continuously updating global treatment guidelines in response to rising antibiotic resistance.
.jpg)
Panel discussion at the Imexforum Hanoi on August 23, 2025. Photo: Imexpharm
Imexpharm continues to expand its anti-infective portfolio, serving a wide range of disease groups, while also broadening its non-antibiotic segments - from chronic disease treatments to wellness-supporting products - to meet Vietnam’s rapidly changing epidemiological landscape.
As part of its commitment to bridging science and community health, Imexpharm organized the 2025 Imexforum Series titled “Advances in Respiratory Infection Diagnosis and Rational Antibiotic Use in Community- and Hospital-Acquired Respiratory Infections.” The series, held from June 21 to August 23, 2025, in Ho Chi Minh City, Da Nang, and Hanoi, gathered leading medical experts to share the latest advances in diagnosis and treatment.
The collaboration of domestic pharmaceutical companies like Imexpharm holds dual significance: it not only enables public access to high-quality medicines but also strengthens Vietnam’s healthcare self-reliance. Above all, Imexpharm remains steadfast in its mission “To provide high-efficacy healthcare solutions for the community” - despite the shifting disease landscape and ever-changing global environment.